Tarsus Pharmaceuticals, Inc. (TARS) News
Follow Tarsus Pharmaceuticals, Inc. (TARS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G Tarsus Pharmaceuticals, Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:27 PM UTC
M
Tarsus Pharmaceuticals Reports Fiscal Q3 Net Loss
Tarsus Pharmaceuticals reported a fiscal 2026 third-quarter net loss attributable to shareholders, down 1,095.37% year over year, and negative basic EPS.
EQUITY | Nov 04, 2026, 06:50 AM UTC
M
Tarsus Pharmaceuticals Q3 Loss Widens as Revenue Rises
Tarsus Pharmaceuticals reported a wider net loss and higher revenue in Q3.
EQUITY | Nov 03, 2026, 10:31 PM UTC
M
Tarsus Pharmaceuticals Reports Q3 Revenue of $194.6M
Tarsus Pharmaceuticals reported Q3 revenue of $194.6 million, versus a FactSet estimate of $187.8 million.
EQUITY | Nov 03, 2026, 10:07 PM UTC
M
Tarsus Pharmaceuticals Posts Q3 Loss of $14.40
Tarsus Pharmaceuticals reported a Q3 loss of $14.40, versus a FactSet estimate of a $1.46 loss.
EQUITY | Nov 03, 2026, 10:00 PM UTC
M
Tarsus Pharmaceuticals Q3 Product Sales Jump 64%, Beat Estimates
EARNINGS | Nov 03, 2026, 09:22 PM UTC
M
Tarsus Reports Q3 2026 Results, XDEMVY Sales Rise 64%
Tarsus reported $194.6 million in XDEMVY net product sales for the third quarter, up approximately 64% year over year. The company said cumulative net product sales since launch exceeded $1 billion and appointed Neera Cl
EQUITY | Nov 03, 2026, 09:17 PM UTC
L
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. NASDAQ:TARS today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual Meet
NEWS | Sep 29, 2026, 12:32 PM UTC
L
Tarsus Pharmaceuticals Price Target Announced at $116.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:14 PM UTC
L
Jefferies raises Tarsus Pharmaceuticals price target to $105, keeps Buy
Jefferies maintained a Buy rating on Tarsus Pharmaceuticals while raising its price target to $105.00 per share from $88.00, according to Benzinga ratings actions.
EQUITY | Sep 08, 2026, 07:00 PM UTC
M
Tarsus Pharmaceuticals completes acquisition of Alkeus, adding Stargardt Phase 3 drug
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine targeting Stargardt’s disease biology. The deal strengthe
MNA | Sep 04, 2026, 12:47 PM UTC
L
Tarsus management to attend upcoming investor conferences
Tarsus Pharmaceuticals said management plans to attend upcoming investor conferences, with live webcasts and additional information available on the events section of the company website.
EQUITY | Sep 01, 2026, 08:37 PM UTC
L
TARS - Tarsus to Participate in Upcoming Investor Conferences
TARS - Tarsus to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 08:30 PM UTC
L
TARS - Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
TARS - Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
EARNINGS | Aug 06, 2026, 11:03 AM UTC
H
Tarsus Pharmaceuticals Raises $125 Million
Tarsus raises $125 million in equity financing
EQUITY | Aug 06, 2026, 11:02 AM UTC
L
TARS - Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
TARS - Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
MNA | Aug 06, 2026, 11:01 AM UTC
L
TARS - Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
TARS - Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
EARNINGS | Aug 06, 2026, 12:02 AM UTC
H
RxSight Names Aziz Mottiwala as CEO
() -- RxSight (RXST) said late Wednesday its board has appointed Aziz Mottiwala as president and chief executive officer, starting July 20. Mottiwala succeeds Ron Kurtz, who will continue to serve as chief medical office
EARNINGS | Jul 15, 2026, 08:43 PM UTC
H
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme
Tarsus Pharmaceuticals Inc (NASDAQ: TARS ) shares are falling Wednesday. Short-seller Culper Research published a report claiming the company’s sole commercial product relies on an alleged illegal Medicare copay scheme.
RATES | Jul 01, 2026, 06:13 PM UTC
L
Watching Tarsus Pharmaceuticals; Shares Move Lower, Culper Research Issues Report On Co Titled "XDEMVY’s Charitable Foundation Scheme, Speci
Watching Tarsus Pharmaceuticals; Shares Move Lower, Culper Research Issues Report On Co Titled "XDEMVY’s Charitable Foundation Scheme, Specialty Pharmacy Gimmicks, and Make-Believe TAM"; Holds A Short Position
EQUITY | Jul 01, 2026, 05:07 PM UTC